110 related articles for article (PubMed ID: 34669636)
1. Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma.
Liu XL; Bai RL; Chen X; Zhao YG; Wang X; Ma KW; Tian HM; Han FJ; Liu ZL; Yang L; Li W; Gai F; Cui JW
Chin Med J (Engl); 2021 Sep; 134(20):2430-2437. PubMed ID: 34669636
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma].
Cao Z; Wang J; Qin N; Li K; Lv J; Wang J; Yang X; Li X; Zhang H; Zhang Q; Long H; Shu C; Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):84-90. PubMed ID: 32093452
[TBL] [Abstract][Full Text] [Related]
3. Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.
Li Y; Xu H; Su S; Ye J; Chen J; Jin X; Lin Q; Zhang D; Ye C; Chen C
PLoS One; 2017; 12(8):e0183331. PubMed ID: 28829813
[TBL] [Abstract][Full Text] [Related]
4. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
5. Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A.
Park CK; Lee SY; Lee JC; Choi CM; Lee SY; Jang TW; Oh IJ; Kim YC
Thorac Cancer; 2021 Feb; 12(4):444-452. PubMed ID: 33270375
[TBL] [Abstract][Full Text] [Related]
6. Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.
Long C; Li K; Liu Z; Zhang N; Xing X; Xu L; Gai F; Che N
Cancer Med; 2023 Apr; 12(7):7982-7991. PubMed ID: 36621813
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer.
Wan R; Wang Z; Lee JJ; Wang S; Li Q; Tang F; Wang J; Sun Y; Bai H; Wang D; Zhao J; Duan J; Zhuo M; An T; Wu M; Chen Z; Yang Z; Wang J
J Thorac Oncol; 2017 Sep; 12(9):1376-1387. PubMed ID: 28552765
[TBL] [Abstract][Full Text] [Related]
8. Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma.
Incharoen P; Jinawath A; Arsa L; Kamprerasart K; Trachu N; Monnamo N; Khiewngam K; Muntham D; Chansriwong P; Sirachainan E; Reungwetwattana T
Cancer Biomark; 2023; 36(1):71-82. PubMed ID: 36530081
[TBL] [Abstract][Full Text] [Related]
9. Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma.
Cui S; Ye L; Wang H; Chu T; Zhao Y; Gu A; Xiong L; Shi C; Jiang L
Clin Lung Cancer; 2018 May; 19(3):e313-e322. PubMed ID: 29329944
[TBL] [Abstract][Full Text] [Related]
10. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
Arrieta O; Hernandez-Martinez JM; Montes-Servín E; Heredia D; Cardona AF; Molina-Romero C; Lara-Mejía L; Diaz-Garcia D; Bahena-Gonzalez A; Mendoza-Oliva DL
Cancer Biomark; 2021; 32(2):123-135. PubMed ID: 34057135
[TBL] [Abstract][Full Text] [Related]
11. Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day.
Wang J; Bai H; Hong C; Wang J; Mei TH
Thorac Cancer; 2017 Jul; 8(4):312-319. PubMed ID: 28437026
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of droplet digital polymerase chain reaction method in detecting plasma circulating tumor deoxyribonucleic acid epidermal growth factor receptor mutations in advanced pulmonary adenocarcinoma patients].
Ma L; Lü JL; Li K; Wang JH; Yang XJ; Li X; Zhang H; Zhang Q; Qin N; Zhang SC
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(29):2336-2340. PubMed ID: 30107692
[No Abstract] [Full Text] [Related]
14. Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.
Xu J; Liu Z; Bai H; Dong G; Zhong J; Wan R; Zang A; Li X; Li Q; Guo J; Du N; Zhong D; Huang Y; Lv Q; Zhang J; Zhao Y; Gao L; Li L; Zhang C; Zhao J; Li B; Liu Z; Yang Z; Ji D; Wang T; Duan J; Wang Z; Wang J
JAMA Oncol; 2022 Sep; 8(9):1328-1332. PubMed ID: 35862035
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.
Riudavets M; Lamberts V; Vasseur D; Auclin E; Aldea M; Jovelet C; Naltet C; Lavaud P; Gazzah A; Aboubakar F; Dorta M; Remon J; Rouleau E; Ngocamus M; Nicotra C; Lacroix L; Besse B; Mezquita L; Planchard D
Clin Lung Cancer; 2022 Sep; 23(6):e377-e383. PubMed ID: 35660356
[TBL] [Abstract][Full Text] [Related]
16. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment.
Zhu L; Zhang S; Xun Y; Jiang Y; Xia B; Chen X; Wang L; Jiang H; Ma S
Pathol Oncol Res; 2018 Oct; 24(4):843-851. PubMed ID: 28868565
[TBL] [Abstract][Full Text] [Related]
18. ctDNA from body fluids is an adequate source for
Pérez-Barrios C; Sánchez-Herrero E; Garcia-Simón N; Barquín M; Clemente MB; Provencio M; Romero A
Clin Chem Lab Med; 2021 Jun; 59(7):1221-1229. PubMed ID: 33691348
[TBL] [Abstract][Full Text] [Related]
19. Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
Roh MS; Yoon NB; Lee S; Kang BH; Um SJ; Lee DH; Son C
J Cancer Res Ther; 2020; 16(4):843-849. PubMed ID: 32930128
[TBL] [Abstract][Full Text] [Related]
20. Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
Duan J; Xu J; Wang Z; Bai H; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Han J; Wang D; Tian Y; Yang Z; Zhang L; Chuai S; Ye J; Zhu G; Zhao J; Wu YL; Wang J
J Thorac Oncol; 2020 Dec; 15(12):1857-1870. PubMed ID: 32916309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
